Ioana Preston, MD, discusses unmet needs in the management of pulmonary arterial hypertension (PAH) and the challenges associated with the progressive nature of the disease.
The pulmonary arterial hypertension (PAH) treatment market stands as a beacon of hope for individuals grappling with this rare but serious condition that affects the heart and lungs. PAH involves abnormally high blood pressure in the arteries that connect the heart and lungs, leading to reduced blood flow and strain.